Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

Rhea-AI Summary

Bio-Path Holdings (BPTH) has announced a corporate update conference call and audio webcast scheduled for May 29, 2025, at 8:30 a.m. ET. The company, which specializes in DNAbilize® antisense RNAi nanoparticle technology, will provide a comprehensive business overview during the call.

Bio-Path's pipeline includes several key candidates: prexigebersen (BP1001) in Phase 2 for blood cancers, BP1001-A in Phase 1/1b for solid tumors and obesity treatment, and BP1002 targeting Bcl-2 protein for blood cancers and solid tumors. Additionally, the company plans to file an IND application for BP1003, a STAT3 inhibitor.

HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview.

To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize^®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. BP1001-A is also being evaluated as a treatment for obesity and related metabolic diseases in Type 2 diabetes patients. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including acute myeloid leukemia. In addition, an IND application is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:
                        
Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com  

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

FAQ

When is Bio-Path Holdings (BPTH) hosting its corporate update conference call in May 2025?

Bio-Path Holdings will host its corporate update conference call on Thursday, May 29, 2025, at 8:30 a.m. ET.

What clinical trials is Bio-Path Holdings (BPTH) currently conducting?

Bio-Path is conducting a Phase 2 study of prexigebersen (BP1001) for blood cancers, a Phase 1/1b study of BP1001-A for solid tumors and obesity, and is evaluating BP1002 for blood cancers and solid tumors.

How can investors access Bio-Path Holdings' May 2025 conference call?

Investors can access the call by dialing (844) 481-3014 (domestic) or (412) 317-1879 (international), or via audio webcast on the Presentations section of www.biopathholdings.com.

What is Bio-Path Holdings' main technology platform?

Bio-Path's main technology platform is DNAbilize®, a novel RNAi nanoparticle technology that allows drug administration through simple intravenous infusion.